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Keratins are the intermediate ﬁlament proteins specifically expressed by epithelial cells. The Human Genome
Project has uncovered a total of 54 functional keratin genes that are differentially expressed in specific epithelial
structures of the body, many of which involve the epidermis and its appendages. Pachyonychia congenita (PC) is a
group of autosomal dominant genodermatoses affecting the nails, thick skin and other ectodermal structures,
according to specific sub-type. The major clinical variants of the disorder (PC-1 and PC-2) are known to be caused
by dominant-negative mutations in one of four differentiation-specific keratins: K6a, K6b, K16, and K17. A total of
20 human keratin genes are currently linked to single-gene disorders or are predisposing factors in complex traits.
In addition, a further six intermediate ﬁlament genes have been linked to other non-epithelial genetic disorders. We
have established a comprehensive mutation database that catalogs all published independent occurrences of
intermediate ﬁlament mutations (http://www.interﬁl.org), with details of phenotypes, published papers, patient
support groups and other information. Here, we review the genotype–phenotype trends emerging from the spec-
trum of mutations in these genes and apply these correlations to make predictions about PC phenotypes based on
the site of mutation and keratin pair involved.
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The main stress-bearing structure within the cytoplasm of
epithelial cells is the keratin intermediate filament cytoskel-
eton (Fuchs and Cleveland, 1998; Coulombe and Omary,
2002; Omary et al, 2004). Dominant-negative mutations in
these genes result in extreme fragility of the cells expressing
the mutant polypeptide (McLean and Lane, 1995; Irvine and
McLean, 1999). Since keratin genes exhibit strictly com-
partmentalized expression patterns in specific epithelial cell
layers (Lane, 1993), each of the known keratin diseases are
characterized by mechanical fragility and usually, compen-
satory overgrowth (hyperkeratosis), of particular epithelial
tissues (Irvine and McLean, 1999). The 27 type I and 27 type
II keratin genes make up the majority of the 65 intermediate
filament genes unearthed by the Human Genome Project
(Hesse et al, 2001; Hesse et al, 2004) and 20 keratin genes
are now linked to human epithelial fragility disease pheno-
types (Smith, 2003; Winter et al, 2004; van Steensel et al,
2005). An additional six non-keratin intermediate filament
genes are involved in a wide range of genetic disorders
mainly affecting non-epithelial tissues.
The clinical features of PC and closely related allelic dis-
orders (focal non-epidermolytic palmoplantar keratoderma,
FNEPPK; steatocystoma multiplex) are reviewed in this
issue (Leachman et al). The genetic basis of these disorders
is also outlined in this issue (Smith et al). Briefly, mutations in
keratins K6a or K16 cause the PC-1 or FNEPPK pheno-
types, whereas K6b or K17 defects cause PC-2 or steatocy-
stoma multiplex phenotypes. With the increasing number of
pathogenic defects being reported in intermediate filament
genes and at the suggestion of the Human Genome Vari-
ation Society (HGVS; formerly the HUGO Mutation Data-
base Initiative), we recently set up an internet-based
database to catalog all intermediate filament mutations
reported in peer-reviewed papers (http://www.interfil.org).
Here, we summarize the spectrum of mutations observed in
keratin genes with reference to severe versus mild pheno-
types, based on the current build of the database. In ad-
dition, we apply these trends to make some broad
predictions about pachyonychia congenita (PC) phenotypes
based on the keratin pair affected and the specific protein
domain where mutations are identified.
Results and Discussion
The human intermediate ﬁlament database The data-
base (http://www.interfil.org) is a freely accessible and
searchable internet-based resource that contains all the
published mutations in the 26 intermediate filament genes
linked to human diseases. The mutations are identified by
regular scanning of the literature by the database curator
(one of us, A. J. C.) and are given a unique identifier number
Abbreviations: EBS, epidermolysis bullosa simplex; FNEPPK, focal
non-epidermolytic palmoplantar keratoderma; PC, pachyonychia
congenita
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based on the date of acceptance of the relevant publication.
Source references and abstracts are given for each report-
ed mutation. Care is taken to avoid duplication of mutations
that are mentioned in more than one paper (e.g., in a ge-
netics paper and perhaps a related clinical case report),
however, independent examples of the same mutations are
included so that mutation clusters and hotspot codons can
be recognized. The individual reference sequences used for
mutation nomenclature are available within the database
and these are reviewed frequently in light of revisions to the
human genome sequence. Mutations and polymorphisms
are named in accordance to the published HUGO guide-
lines (Antonarakis, 1998; Dunnen and Antonarakis, 2000)
and where the authors have used non-standard nomencla-
ture, this is corrected in the database entry with an anno-
tation to show that there has been an alteration. Thus, the
corrected data allows comparisons to be made without
confusion. Furthermore, the database contains amino acid
reference sequences that have been annotated to show the
positions of functional protein domains. The protein domain
affected is listed with individual mutations to allow compar-
isons to be made between different keratins or other inter-
mediate filament genes. There are also brief clinical
descriptions of the various intermediate filament disease
phenotypes as well as links to the clinical genetics database
OMIM, patient advocacy groups and other useful sites. It is
hoped that this database will be a central resource for the
field, allowing genotype–phenotype and structure–function
correlations to be made based on continuously updated data.
Types and numbers of mutations There are currently 417
independently occurring dominant keratin mutations logged
in the intermediate filament mutation database (http://
www.interfil.org). Of these, 381 ( 91.5%) are missense
mutations, 28 ( 6.5%) are small in-frame insertion/deletion
mutations and 6 ( 1.5%) are intronic splice site defects
leading to larger in-frame deletions. Two out-of-frame de-
letions have also been reported affecting the tail domain of
K1. Examples of the relative positions of the reported mu-
tations in keratins are summarized (Fig 1). At the protein
level, the functional consequences of these molecular de-
fects are similar in that they all lead to expression of mutant
polypeptides at normal or near-normal levels carrying amino
acid substitutions, deletion of one or more amino acids, or
in a few cases, insertion of foreign amino acids. All of these
defective proteins are able to form heterodimers with the
wild-type keratin partner protein and thereby integrate into
the keratin network where they cause weakening or collapse
of the cytoskeleton through the mechanism of dominant-
negative interference. An example of transient expression of
a K16 missense mutation from a PC-1 family, L124R, in
cultured epithelial cells is shown (Fig 2), illustrating the
complete collapse of the endogenous keratin cytoskeleton.
Epidermolysis bullosa simplex (EBS) as a prototypic
keratin disease The inherited skin blistering disorder EBS
was the first keratin disorder to be discovered in the early
1990s and is considered one of the most severe keratin
disease phenotypes (Bonifas et al, 1991; Coulombe et al,
1991; Lane et al, 1992). Histologically, there is cytolysis and
blistering through the basal cell layer of the epidermis in all
subtypes of EBS and the major forms of the disease are
caused by mutations in either keratin K5 or K14, the inter-
mediate filament proteins specifically expressed within this
cell compartment (Irvine and McLean, 1999; Smith, 2003).
EBS differs from the other disorders in this group in as much
as there are a number of well-defined clinical subtypes
with varying degrees of severity (Fine et al, 1991, 2000).
Figure 1
Schematic diagram showing the protein do-
main organization of type I/II keratins. The rod
domain consists of a-helical segments 1A, 1B,
2A and 2B, separated by non-helical linkers L1,
L12 and L2. The highly conserved helix initiation
and termination motifs are shaded red and
green, respectively. The rod domain is flanked
by variable head and tail domains, V1 and V2.
Within the head and tail are short homology
subdomains, H1 and H2, respectively, which are
largely specific to type II keratins. (A) Positions
and numbers of the reported dominant muta-
tions in K5 and K14 causing epidermolysis
bullosa simplex (EBS), revealing the mutation
clusters associated with severe generalized
(pink) and mild, site-restricted (yellow) EBS phe-
notypes. Note that the helix boundary motifs are
hotspots for the more severe Dowling–Meara
form of EBS. (B) Positions and numbers of the
reported dominant mutations in K6a, K6b, K16,
and K17 causing pachyonychia congenita (PC).
Note that most of the reported mutations in the
classical PC-1 and PC-2 subtypes occur in the
helix boundary motifs and relatively few are
found elsewhere, implying that milder PC phe-
notypes may not always present clinically. Note
also that some mutations in the helix boundary
motifs lead to milder, site-restricted clinical phe-
notypes (yellow), specifically focal non-epi-
dermolytic palmoplantar keratoderma (FNEPPK)
(a variant of PC-1) and steatocystoma multiplex
(an allelic form of PC-2). Note that the two re-
ports so far of late-onset PC (shaded orange)
occur in sites analogous to the milder EBS mu-
tations (shown in A).
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Specifically, the Dowling–Meara form of EBS (EBS-DM)
is the most severe and is life-threatening in neonates. This
type of EBS is characterized by very widespread, clustered
blisters and is often accompanied by fairly severe palmo-
plantar keratoderma. Ultrastructurally, EBS-DM can be di-
agnosed by the appearance of electron-dense cytoplasmic
aggregates (Anton-Lamprecht and Schnyder, 1982), which
by immuno-electron microscopy, have been shown to con-
sist of abnormally folded and condensed K5 and K14 (Is-
hida-Yamamoto et al, 1991). In contrast, patients with the
Weber–Cockayne variant (EBS-WC) normally have blisters
only on the hands and feet, although they will develop blis-
ters elsewhere with the application of sufficient mechanical
trauma. The Ko¨bner form of EBS (EBS-K) is intermediate in
severity between EBS-DM and EBS-WC, with blisters on
the hands and feet and elsewhere, but without the charac-
teristic clustering of lesions seen in EBS-DM. There is clear-
ly room for overlap in these milder phenotypes and many
clinicians do not distinguish EBS-K and EBS-WC but rather
group these together under the EBS-WC title (particularly in
the UK and Europe). By electron microscopy, the basal cell
keratin filaments appear to be more or less normal in the
milder forms of EBS. Another mild variant of EBS is the form
associated with mottled pigmentation (EBS-MP). This is
again very similar to EBS-WC in severity but can be readily
distinguished clinically by the pigmentory changes specific
to this variant.
Genotype–phenotype correlation in EBS and other dis-
orders From the many reported EBS mutations in K5 and
K14 (128 at the time of writing), about six mutation ‘‘hot-
spots’’ have emerged, as illustrated (Fig 1). The highly con-
served helix boundary motifs of both proteins are the major
hotspots that were identified early on in EBS-DM patients.
These short (20 amino acids) sequence motifs that mark
the beginning and end of the keratin rod domain, are known
to be involved in critical molecular overlap interactions in
the assembly of keratin filaments from their small hetero-
dimer subunits. Thus, mutations in these motifs interfere
with the early stages of filament elongation and result in
negligible or very poor filament assembly. The unpolymer-
ized keratins form dense cytoplasmic aggregates as seen in
cultured cells (Fig 2) or in the skin of EBS-DM patients by
electron microscopy (Anton-Lamprecht and Schnyder,
1982; Ishida-Yamamoto et al, 1991).
The milder EBS-K and EBS-WC variants are associated
with mutations in a small number of discrete sites elsewhere
along the keratin molecule. Specifically, these are the H1
domain of K5; and the second half of the 1A domain, the L12
domain, and central 2B domain of both proteins. One par-
ticular mutation, P25L in the V1 domain of K5, has been
reported in all cases of EBS-MP characterized to date. The
mechanism by which this particular mutation leads to ab-
normal pigmentation remains unknown. Because they do
not interfere with the elongation process during filament as-
sembly, all these milder mutations allow formation of normal-
looking keratin filaments but result in structurally weakened
filaments that break under mild mechanical stress. These
weak filaments, however, provide cells with more structural
resilience than the completely aggregated keratins found in
EBS-DM keratinocytes and so it requires more trauma to
induce cell lysis and blistering, i.e., milder, EBS phenotypes
restricted to high trauma sites such as hands and feet.
Therefore, based on the site of a mutation in K5 or K14, it
is largely possible to predict the resulting phenotype (Irvine
and McLean, 1999; Smith, 2003). This is particularly useful
in the diagnosis of infants with EBS where the clinical dif-
ferences between the subtypes are less obvious. Molecular
analysis in these cases can inform families and their clini-
cians at this early stage as to what the likely longer-term
outcome will be, so that appropriate interventions can be
taken. In the other keratin disorders, genotype–phenotype
correlation is less of an issue and the vast majority of re-
ported mutations occur in the helix boundary motif regions.
Figure 2
Transient transfection of simple epithelial cell line PtK2 with hu-
man K16 missense mutant L124R cDNA expression construct, as
reported previously (Smith et al, 2000). (A) Expression of endogenous
keratins in PtK2 cells (stained green with K8 monoclonal antibody
LE41). A widespread network of fine intermediate filament bundles is
visible in all cells. Nuclei counterstained blue with 40,6-diamidino-2-
phenylindole (DAPI). (B) Expression of the construct carrying missense
mutation L124R in the helix initiation motif of K16 leads to formation
of dense cytoplasmic keratin aggregates in a high percentage of
transfected cells (K16 stained green with monoclonal antibody LL0025).
Nuclei counterstained blue with DAPI.
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PC is one exception where some milder related phenotypes
are now known, as will be discussed in detail below. An-
other exception is the case of K1, in which certain mutations
have been shown to produce milder site-restricted pheno-
types, compared with the severe generalized epidermolytic
hyperkeratosis phenotype normally associated with K1
and K10 mutations (bullous congenital ichthyosiform er-
ythroderma). Some of these are missense mutations in the
helix boundary motifs—such as I479T in the helix termina-
tion motif of K1, which has been associated with mild
ichthyosis-like phenotype in some cases (Sybert et al, 1999)
and epidermolytic palmoplantar keratoderma alone in other
families (Terron-Kwiatkowski et al, 2004). It is not clear why
this mutation, which occurs in a region normally associated
with severe phenotypes in other keratins, results in a mild
phenotype where K1 is concerned. Larger in-frame dele-
tions in K1 have also been shown to result in epidermolytic
palmoplantar keratoderma—known as ‘‘K1 keratoderma’’
(Hatsell et al, 2001; Terron-Kwiatkowski et al, 2002). It may
be that these larger deletions, particularly those removing
substantial portions of the boundary motif sequences,
render the mutant polypeptide less able to assemble and
are therefore less disruptive. This seems to be the case with
a similar deletion in K16 leading to a mild PC-related phe-
notype, discussed below (Smith et al, 2000).
Emerging genotype–phenotype trends in PC As is the
case with most non-EBS keratin mutations, the vast major-
ity of the pathogenic defects in the PC-1 keratins (K6a, K16)
and the PC-2 keratins (K6b, K17) occur in the helix bound-
ary motifs of these proteins, including the novel and recur-
rent mutations reported elsewhere in this issue (Smith et al).
The phenotypes in these cases are fairly consistent—typical
severe nail dystrophy and other ectodermal features. In
keeping with the other keratins, the majority of these mu-
tations are missense changes, with a smaller number of in-
frame insertions or deletions.
Two milder phenotypic variants of PC-1 and PC-2 have
been recognized, FNEPPK and steatocystoma multiplex,
respectively, as discussed above. Certain K16 defects have
been reported to cause FNEPPK: these are the missense
mutations N125S and R127C in the helix initiation motif
(Shamsher et al, 1995); and a complex 24 bp deletion in the
helix termination motif of the K16 polypeptide—a deletion of
23 bp and a separate 1 bp deletion nearby (Smith et al,
2000). Elsewhere in this issue, two independent occurrenc-
es of the N125S mutation are reported (Smith et al). In one
of these families, this mutation is again associated with a
milder phenotype consisting of FNEPPK with trivial nail
changes. The other family, however, presented with a more
classical PC-1 phenotype including hypertrophic dystrophy
of most nails. Therefore, N125S appears to be more often,
but not always, associated with the milder phenotype.
These cases emphasize the importance of not basing hard
and fast conclusions about genotype–phenotype correla-
tion on small numbers of families. Interestingly, a second
family with the FNEPPK phenotype studied by Smith et al
(this issue), carried the R127C mutation in K16, which has
also been reported previously in association with this milder
presentation (Shamsher et al, 1995). The equivalent muta-
tion in K14 (R125C) consistently results in the severe EBS-
DM phenotype (Coulombe et al, 1991; http://www.interfil.
org). Thus, there may be more genetic or environmental
modifiers at play in PC compared with EBS.
The second type of mutation associated with FNEPPK,
the complex 24 bp deletion involving the helix termination
motif of K16 (Smith et al, 2000), is similar in its effect to the
deletions seen in K1 that produce milder, body site restrict-
ed phenotypes (Hatsell et al, 2001; Terron-Kwiatkowski
et al, 2002). In the case of this K16 mutation, protein ex-
pression studies in cultured cells showed that the deletion
appears to have less detrimental effects on the endogenous
cytoskeleton compared to missense mutations (Smith et al,
2000). This is consistent with the idea that these types of
mutations render the mutant protein less able to interact
with and therefore disrupt wild-type keratin subunits.
In the case of steatocystoma multiplex, a milder, pheno-
typically restricted ‘‘relative’’ of PC-2, only a few mutations
have been reported to date, all in the helix initiation motif of
K17, specifically, N92H, R94H, and R94C (Smith et al, 1997;
Covello et al, 1998; Wang et al, 2001). What is particularly
interesting here is the fact that mutation R94C was reported
in one family causing the classic PC-2 phenotype but in two
other unrelated kindreds, gave the steatocystoma multiplex
phenotype without significant nail changes (Covello et al,
1998; Wang et al, 2001). In each case, the phenotype was
consistent within the family. This clearly demonstrates that
there are genetic background effects i.e. modifying genes or
other factors, that can alter the severity of the PC pheno-
type. Similar phenotypic variation has been observed in
most or all of the known keratin disorders but the identity of
the modifying factors underlying this epiphenomenon re-
mains unknown. This also has important consequences for
making genotype–phenotype correlations and predictions
about future disease patterns or severity based on molec-
ular data. For example, the equivalent mutation in K14
(R125C) to the steatocystoma defect R94C consistently
produces the EBS-DM phenotype (Coulombe et al, 1991).
Therefore caution should be exercised when making prog-
nostic predictions based on a relatively small sample of
mutation-phenotype data.
To date, no K6a mutations have been reported in
FNEPPK families, although we have looked for these with-
out success (Smith and McLean, unpublished observa-
tions). Similarly, no K6b mutations have been seen in
steatocystoma multiplex. Since type II keratin mutations
accurately phenocopy the respective type I mutations in
PC-1 and PC-2, there is no obvious reason why K6a and
K6b mutations would not occur in association with milder
presentations. Again, the overall numbers of mutations in
these genes are somewhat small at this stage.
Mild mutations may modulate age of onset in PC Nor-
mally, PC is evident in the first months of life, either as skin
blistering, hyperkeratosis or nail dystrophy. One clinical
variant of PC has been described where there is a relatively
late age of onset, described as PC-tarda. Recently, the
molecular defects underlying two cases of PC-tarda have
been identified. In the first case, a missense mutation,
K354N, located in the central 2B domain of K16, was iden-
tified in a case of late-onset PC-1 (Connors et al, 2001). In
the second case, reported very recently, late-onset PC-2
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was found to be caused by a missense mutation in the
second half of the 1A domain of K17, N109D (Smith, 2004;
Xiao et al, 2004). Significantly, both of these mutations oc-
cur in regions equivalent to the hotspots of K5 and K14 that
are associated with the mild EBS-WC/EBS-K phenotypes
(Fig 1). Thus, two mutations of a type that would result in a
mild EBS phenotype if they occurred in K5 or K14, here led
to delayed onset PC. As stated above, it is not advisable to
draw firm genotype–phenotype conclusions based on very
small numbers of mutations, however, these results perhaps
point to an emerging trend where mutations in L12 domain
of K6a, K6b, K16, and K17 or the H1 subdomain of the type
II keratins, might be predicted to give late-onset pheno-
types. Further mutation analysis should confirm these
trends in the future.
Keratin polymorphisms and modiﬁer genes Recently,
there has been a report of a second modifying mutation
within a keratin gene (Yasukawa et al, 2002). In this study, a
family presented with several members affected by autos-
omal dominant EBS, some of whom were mildly affected,
whilst others quite severely affected by skin blistering. All
the affected persons, regardless of severity, carried a mu-
tation in the 1A domain of K5, E170K. The more severely
affected individuals also carried a second mutation on the
other K5 allele, E418K in the center of the 2B domain. In-
terestingly, a number of people in the family carried only the
E418K mutation and had no skin blistering phenotype
whatsoever, even though this mutation was shown to pro-
duce a low level of keratin aggregation when expressed in
cultured cells (Yasukawa et al, 2002). Neither of these mu-
tations were detected in 100 ethnically matched chromo-
somes and so were not common sequence variants in the
population. Thus, the E418K mutation acts as a polymorph-
ism in the heterozygous state but is able to exacerbate a
mild EBS phenotype when in the compound heterozygous
state. It is not known what the effect of a homozygous
E418K mutation would be in humans but it is quite possible
that this might produce recessive EBS, similar to other re-
ports in the literature (Hovnanian et al, 1993). This study
points the way towards understanding at least some of the
factors involved in generating phenotypic variation within a
kindred with a given mutation. Very often, genetic testing
laboratories do not fully screen genes but halt the screening
process as soon as a mutation is detected and confirmed.
This is a particularly common practice in keratin gene
screening since analysis generally starts with the most
prevalent mutation hotspots (Fig 1) and only when these are
negative, are the other exons or other keratin genes
screened. Thus, important modifying factors within a ker-
atin pair can easily go unnoticed.
To date, there has been no formal publication of non-
pathogenic polymorphisms in the keratin genes causing PC,
although from our own screening program, we have identi-
fied a number of mainly silent polymorphisms in these genes,
e.g., A161A and E165E in the K6a gene (Smith, unpublished
data). Furthermore, there are many single nucleotide poly-
morphisms in the genome database involving these genes,
several of which affect exons (http://genome.ucsc.edu).
Therefore, there is some potential for keratin polymorphisms
acting as phenotypic modifiers in PC and full sequencing of
K6a, K6b, K16, and K17 genes might help identify these
genetic modifiers within families presenting with highly var-
iable phenotypes (see Leachman et al, this issue).
Conclusions
There are four main conclusions to draw from the study of
mutations in PC. Firstly, and consistently to date, mutations
in K6a or K16 give rise to the PC-1 phenotype whereas K6b
or K17 mutations result in the more complex PC-2 pheno-
type. Secondly, certain mutations in K16 can give rise to the
milder FNEPPK phenotype and similarly, a subset of mu-
tations in K17 cause steatocystoma multiplex. Thirdly, some
keratin mutations can produce mild or severe phenotypes in
different families/ethnic backgrounds, pointing to the exist-
ence of unknown genetic and/or environmental modifying
factors and a need for caution in predicting phenotypes
purely from mutational data. Finally, as well as milder site-
restricted phenotypes, some mutations, particularly those
similar to the milder EBS mutations, may lead to delayed
onset forms of PC.
There is still much to learn about the genetics of PC. In
our experience, about 10% of PC patients referred to our
laboratory for diagnostic testing lack detectable mutations
in any of the four appropriate keratins. Although we were
able to account for some of these missing mutations by the
misdiagnosis of Clouston syndrome patients who carry
connexin 30 defects but resemble PC clinically (van
Steensel et al, 2003), there still remain a group of PC pa-
tients who lack mutations. Some of these may have larger
genomic deletions, duplications or other rearrangements
that go undetected using the normal exon-by-exon PCR
mutation detection strategies. Since the keratins involved in
PC have multiple pseudogenes and/or isogenes, these
types of mutations may not be uncommon, as is the case
for other clusters of highly homologous genes, such as the
globin genes (Cooper and Krawczak, 1993). Southern blot
analysis or the recently developed MLPA technique (multi-
plex ligation-dependent probe amplification) could be used
to detect these types of defects (Schouten et al, 2002). Ac-
tivation of a partly translatable keratin pseudogene carrying
missense mutations or other sequence changes is another
possibility, if a genomic rearrangement placed such a gene
downstream of an active keratin promoter. There is also the
possibility that mutations in other K6 isoforms, such as K6hf
or others (Takahashi et al, 1995; Winter et al, 1998), may
cause variants of PC that phenotypically resemble PC-1 or
PC-2. The recent completion of the human genomic se-
quence across the type I and II keratin gene clusters should
facilitate identification of these more cryptic types of PC
mutation and may also aid in elucidation of some of the
genetic modifying factors involved. Overall, this should lead
to a fuller understanding of the molecular basis of PC, im-
prove diagnostic testing and ultimately, help in the rational
design of therapies for this group of incurable diseases.
Materials and Methods
Software Adobe GoLive CS web design software (Adobe Systems
Inc., San Jose, CA) was used to create the HTML code which
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provides an interface to the Database information. The Database itself
is contained within a FileMaker Pro 6 document and is shared across
the internet using FileMaker Web Companion. Graphics were created
using a combination of Adobe Photoshop and Macromedia Fire-
works. The website is administrated using Mac OS X Server software.
Hardware The database is run on an Apple G5 Dual 2.5 GHz
PowerPC (Apple, Cupertino, CA). Data is regularly backed up using
a Hewlett-Packard Ultrium 215 tape drive (Hewlett-Packard, Palo,
Alto, CA.
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